Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

These viruses have only the capsid surrounding their genetic material. A virus budding from a host cell membrane. This sequence of steps forms the virus’s envelope. A host is an organism that a ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV replication. Unlike traditional antiretrovirals that target enzymes such as ...

Many pathogenic viruses require a specific structure to be infectious, and their proteins form that structure in vivo with remarkable fidelity. The dynamical process by which protein conformations are ...

1, lower right). Concurrent experiments by the group of C. Knobler and W. Gelbart (UCLA), in which capsid proteins assemble around RNA molecules with lengths in excess of the viral genome length, ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...